125 related articles for article (PubMed ID: 18329610)
1. A new antituberculosis drug that selectively kills nonmultiplying Mycobacterium tuberculosis.
Mitchison DA
Cell Host Microbe; 2008 Mar; 3(3):122-4. PubMed ID: 18329610
[TBL] [Abstract][Full Text] [Related]
2. Selective killing of nonreplicating mycobacteria.
Bryk R; Gold B; Venugopal A; Singh J; Samy R; Pupek K; Cao H; Popescu C; Gurney M; Hotha S; Cherian J; Rhee K; Ly L; Converse PJ; Ehrt S; Vandal O; Jiang X; Schneider J; Lin G; Nathan C
Cell Host Microbe; 2008 Mar; 3(3):137-45. PubMed ID: 18329613
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, SAR and biological investigation of 3-(carboxymethyl)rhodanine and aminothiazole inhibitors of Mycobacterium tuberculosis Zmp1.
Mori M; Deodato D; Kasula M; Ferraris DM; Sanna A; De Logu A; Rizzi M; Botta M
Bioorg Med Chem Lett; 2018 Feb; 28(4):637-641. PubMed ID: 29395975
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.
Shaikh MS; Kanhed AM; Chandrasekaran B; Palkar MB; Agrawal N; Lherbet C; Hampannavar GA; Karpoormath R
Bioorg Med Chem Lett; 2019 Aug; 29(16):2338-2344. PubMed ID: 31227345
[TBL] [Abstract][Full Text] [Related]
5. Quinolidene-rhodanine conjugates: Facile synthesis and biological evaluation.
Subhedar DD; Shaikh MH; Shingate BB; Nawale L; Sarkar D; Khedkar VM; Kalam Khan FA; Sangshetti JN
Eur J Med Chem; 2017 Jan; 125():385-399. PubMed ID: 27688192
[TBL] [Abstract][Full Text] [Related]
6. Novel imidazo[2,1-b][1,3,4]thiadiazole carrying rhodanine-3-acetic acid as potential antitubercular agents.
Alegaon SG; Alagawadi KR; Sonkusare PV; Chaudhary SM; Dadwe DH; Shah AS
Bioorg Med Chem Lett; 2012 Mar; 22(5):1917-21. PubMed ID: 22325950
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mycobacterial Activity of Tamoxifen Against Drug-Resistant and Intra-Macrophage Mycobacterium tuberculosis.
Jang WS; Kim S; Podder B; Jyoti MA; Nam KW; Lee BE; Song HY
J Microbiol Biotechnol; 2015 Jun; 25(6):946-50. PubMed ID: 25639719
[TBL] [Abstract][Full Text] [Related]
8. Structure prediction, molecular simulations of RmlD from Mycobacterium tuberculosis, and interaction studies of Rhodanine derivatives for anti-tuberculosis activity.
N H; P SR; Sura M; Daddam JR
J Mol Model; 2021 Feb; 27(3):75. PubMed ID: 33547544
[TBL] [Abstract][Full Text] [Related]
9. Bridging the gap between a TB drug and its target.
Cook GM; Heikal A
Sci Transl Med; 2012 Sep; 4(150):150fs33. PubMed ID: 22956196
[TBL] [Abstract][Full Text] [Related]
10. Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs.
Coleman D; Waddell SJ; Mitchison DA
J Antimicrob Chemother; 2011 Jan; 66(1):146-50. PubMed ID: 21071459
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
12. Targeting Phenotypically Tolerant Mycobacterium tuberculosis.
Gold B; Nathan C
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28233509
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
Xu JF; Wang TT; Yuan Q; Duan YT; Xu YJ; Lv PC; Wang XM; Yang YS; Zhu HL
Bioorg Med Chem; 2019 Apr; 27(8):1509-1516. PubMed ID: 30846404
[TBL] [Abstract][Full Text] [Related]
14. Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline.
Darby CM; Nathan CF
J Antimicrob Chemother; 2010 Jul; 65(7):1424-7. PubMed ID: 20435781
[TBL] [Abstract][Full Text] [Related]
15. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.
de Carvalho LP; Lin G; Jiang X; Nathan C
J Med Chem; 2009 Oct; 52(19):5789-92. PubMed ID: 19736929
[TBL] [Abstract][Full Text] [Related]
16. [Bacteriological substantiation of the antituberculosis effect of immunotropic drug tubosan].
Kibrik BS; Pavlov AV; Chelnokova OG
Eksp Klin Farmakol; 2013; 76(2):20-2. PubMed ID: 23631279
[TBL] [Abstract][Full Text] [Related]
17. Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis.
Zheng P; Somersan-Karakaya S; Lu S; Roberts J; Pingle M; Warrier T; Little D; Guo X; Brickner SJ; Nathan CF; Gold B; Liu G
J Med Chem; 2014 May; 57(9):3755-72. PubMed ID: 24694175
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development.
Nguyen L; Pieters J
Annu Rev Pharmacol Toxicol; 2009; 49():427-53. PubMed ID: 19281311
[TBL] [Abstract][Full Text] [Related]
19. Application of Continuous Culture for Assessing Antibiotic Activity Against Mycobacterium tuberculosis.
Hendon-Dunn CL; Anwar S; Burton C; Bacon J
Methods Mol Biol; 2018; 1736():59-73. PubMed ID: 29322459
[TBL] [Abstract][Full Text] [Related]
20. New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053.
Chiarelli LR; Salina EG; Mori G; Azhikina T; Riabova O; Lepioshkin A; Grigorov A; Forbak M; Madacki J; Orena BS; Manfredi M; Gosetti F; Buzzi A; Degiacomi G; Sammartino JC; Marengo E; Korduláková J; Riccardi G; Mikušová K; Makarov V; Pasca MR
ACS Infect Dis; 2020 Feb; 6(2):313-323. PubMed ID: 31729215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
